Functional and Structural Insights into the Human PPARα/δ/γ Targeting Preferences of Anti-NASH Investigational Drugs, Lanifibranor, Seladelpar, and Elafibranor

• Main Authors: Shotaro Kamata (Author), Akihiro Honda (Author), Ryo Ishikawa (Author), Makoto Akahane (Author), Ayane Fujita (Author), Chihiro Kaneko (Author), Saeka Miyawaki (Author), Yuki Habu (Author), Yui Shiiyama (Author), Kie Uchii (Author), Yui Machida (Author), Takuji Oyama (Author), Isao Ishii (Author)
• Format: Book
• Published: MDPI AG, 2023-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

No therapeutic drugs are currently available for nonalcoholic steatohepatitis (NASH) that progresses from nonalcoholic fatty liver via oxidative stress-involved pathways. Three cognate peroxisome proliferator-activated receptor (PPAR) subtypes (PPARα/δ/γ) are considered as attractive targets. Althou...